The retailer plans to open stores in Bay Shore and Islandia, and relocate its store in a Massapequa shopping center to a ...

Keytrda “still reigns” after the interim analysis for Akeso and Summit Therapeutics (SMMT)’ PD-1/VEGF “muddies the outlook” for a potential ivonescimab survival benefit in non-small cell lung cancer.

Brian Belski, BMO Capital chief investment strategist, joins 'Squawk on the Street' to discuss his optimism on the markets ...

BMO Capital raised the firm’s price target on Newmont (NEM) to $64 from $63 and keeps an Outperform rating on the shares after its Q1 earnings ...

Bristol Myers Squibb's BMY.N drug to treat a type of heart disease did not significantly improve functional capacity and ...

Stock futures are little changed Wednesday night after a steep sell-off in the prior session. Futures tied to the Dow Jones ...

Eli Lilly said on Thursday its experimental pill, orforglipron, led to a weight loss of nearly 8% at the highest dose and ...

It’s unclear whether tariffs will influence more companies to make more drugs in the U.S. like President Donald Trump is hoping for, some experts said.

“The risk that this escalating trade war tips the world into a recession is rising as the two largest and most powerful ...

The mounting uncertainty has now prompted BMO Capital Markets to lower its year-end target for the benchmark index. “We are revising our 2025 year-end S&P 500 price targets down to 6,100 from 6,700.

PHILADELPHIA, April 9, 2025 /PRNewswire/ -- FMC Corporation (NYSE: FMC) today announced that Pierre Brondeau, FMC chairman and chief executive officer, and Andrew Sandifer, FMC executive vice ...